Why It Matters
Amgen Inc. filed a new lobbying registration on June 12, 2026, bringing on Michael Lamoureux of Capitol Counsel to lobby on medical and disease research issues. The filing comes as the pharmaceutical giant faces a wave of congressional scrutiny over drug pricing and tax practices.
Amgen is no stranger to Washington, but this new lobbying registration adds a fresh outside voice to its federal advocacy operation. Lamoureux, a partner at Capitol Counsel, joins at a moment when pharmaceutical companies are under pressure from multiple directions: Democratic lawmakers demanding transparency on pricing deals with the Trump Administration, and ongoing battles over National Institute of Health (NIH) funding cuts that directly affect the clinical research ecosystem Amgen depends on. Separately, Amgen has been publicly identified as a supporter of the Prescription Information Modernization Act, a bipartisan House bill that would allow the FDA to permit drug manufacturers to send prescribing information electronically rather than on paper. That bill was reintroduced in July 2025 by Rep. Diana Harshbarger (R-TN-1) and Rep. Mikie Sherrill (D-NJ-11).
Broader Context
The lobbying activities described in this registration land in a turbulent policy environment for pharmaceutical and biomedical research.
Sen. Bernie Sanders (I-VT) released a Senate HELP Committee report in February 2026 documenting the defunding of more than 300 clinical trials and cuts of $561 million from research funding.
At the same time, Amgen has been a named target in a coordinated series of Democratic Senate letters demanding transparency on pharmaceutical pricing agreements with the Trump administration. Those letters, sent in March 2026, asked Amgen and a group of other major drug manufacturers to provide current Medicaid net prices and "most favored nation" pricing data.
On taxes, Rep. Janice Schakowsky (D-IL-9) and Sen. Elizabeth Warren wrote to Amgen and four other pharmaceutical companies in June 2025, calling them out for paying $0 in federal taxes on prior-year profits.
The Bottom Line
Amgen's new lobbying registration, covering medical and disease research, arrives during an active period of congressional attention to pharmaceutical pricing, NIH funding, and clinical research. The addition of Lamoureux as a registered lobbyist expands Amgen's outside advocacy capacity.
The lobbying disclosure requirements that apply to Amgen's new registration apply equally to its competitors, and the policy pressure they face from Congress is largely shared.
Spot something wrong? Report an issue with this article